3,000 Patient Clinical Trial

- the leader in infant diagnostic innovations

mHealthcare has secured the ethical IRB approvals for biomedical research involving human subjects. Approved budgets and human capital infrastructure are in place to support a Stage 1 Clinical Study to validate a biomarker for autism with a 95% efficacy, targeted to start in Q3 2023. Parents, if you live in New York state, and your child will be between three to nine months old in July 2023, click the GET IN TOUCH button to learn more about this opportunity and sign up for a safe, secure, in-home, free infant diagnostic screening.

Saving the U.S. Healthcare System over $5B annually

The cost of autism spectrum services to U.S. citizens is $236-262 billion annually. By providing early diagnosis and intervention, mHealthcare’s infant neurological screening platform will significantly reduce the cost of lifelong care. Our infant neurodivergent evaluations are administered quickly, and our value-based care model will save hospitals and Pediatric Physicians time and money, driving early adoption and scalability. Our big data technology could save the U.S. healthcare system over $5 billion annually.